Molecular Formula | C34H40N2O18 |
Molar Mass | 764.68 |
Density | 1.350±0.06 g/cm3(Predicted) |
Melting Point | 86-90°C |
Boling Point | 796.1±60.0 °C(Predicted) |
Solubility | Soluble in chloroform, dimethyl sulfoxide |
Appearance | powder |
Color | White |
Maximum wavelength(λmax) | 287 nm |
BRN | 7458534 |
pKa | 1.69±0.50(Predicted) |
Storage Condition | -20°C |
Stability | Light Sensitive |
Sensitive | Sensitive to heat |
MDL | MFCD00036696 |
Use | A membrane-permeable form of BAPTA;Selective chelator of intracellular Ca2 stores. |
In vitro study | BAPTA-AM, as an intracellular calcium chelator, delayed necrosis was induced by lipoxygenase-mediated free radicals in mouse cortical medium. In HEK 293 cells, BAPTA-AM showed Open Channel blockade of hERG,hKv1.3 and hKv1.5 channels with IC50 of 1.3,1.45 and 1.23 μm. |
In vivo study | In BDL rats, BAPTA-AM abrogated either UDCA-and TUDCA-induced increases in Ca2 levels or Ca2-dependent phosphorylation of PKC-α, and counteracts the cytoprotective effect of UDCA and TUDCA on biliary vagotomy-induced injury. |
Hazard Symbols | Xi - Irritant![]() |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 3 |
FLUKA BRAND F CODES | 8-10-21 |
maximum wavelength (& lambda;max) 287 nm
indicators of applied Calcium in biological field; treating cancer,chronic bacterial infection,glaucoma,ocular hypertension,HIV-associated conditions,infectious diseases,neurodegenerative disorders,neurological conditions,psychiatric conditions
Cell permeability chelating agent BAPTA-AM is a cell permeability chelating agent. The selectivity for Ca2 + exceeds Mg2 + and can be used to control intracellular Ca2 + levels. The selectivity of BAPTA for Ca2 + is stronger than that of EDTA and EGTA, and its metal chelation is relatively less sensitive to pH.
Biological activity
the BAPTA-AM is to select the permeable membrane calcium chelating agent.
In vitro study
BAPTA-AM, as an intracellular calcium chelator, induces delayed necrosis through free radicals mediated by lipoxygenase in mouse cortical medium. In HEK 293 cells, BAPTA-AM showed an open channel blocking effect on hERG,hKv1.3 and hKv1.5 channels with IC50 of 1.3,1.45 and 1.23 μM.
In vivo studies
In BDL rats, UDCA-and TUDCA-induced increases in Ca2 + levels or Ca2 +-dependent PKC-α phosphorylation were BAPTA-AM abolished, and the cytoprotective effects of UDCA and TUDCA on injuries induced by biliary vagotomy were counteracted.
Target
Ca 2 chelator
IC50: 1.3 μM (hERG channel, in HEK 293 cells), 1.45 μM (hKv1.3, in HEK 293 cells), 1.23 μM (hKv1.5, in HEK 293 cells)
cell permeability chelating agent | BAPTA-AM is a cell permeability chelating agent whose selectivity for Ca2 exceeds Mg2 and can be used to control intracellular Ca2 levels. The selectivity of BAPTA for Ca2 + is stronger than that of EDTA and EGTA, and its metal chelation is relatively less sensitive to pH. |
biological activity | BAPTA-AM is to select a permeable membrane calcium chelating agent. |
In vitro studies | BAPTA-AM, as an intracellular calcium chelator, in mouse cortex culture media through lipoxygenase-mediated free radicals induce delayed necrosis. In HEK 293 cells, BAPTA-AM showed an open channel blocking effect on hERG,hKv1.3 and hKv1.5 channels with IC50 of 1.3,1.45 and 1.23 μM. |
In vivo studies | In BDL rats, UDCA-and TUDCA-induced increases in Ca2 levels or Ca2 +-dependent PKC-α phosphorylation were BAPTA-AM abolished, and the cytoprotective effects of UDCA and TUDCA on injuries induced by biliary vagotomy were counteracted. |
target | Ca 2 chelator IC50: 1.3 μ m (hERG channel, in HEK 293 cells), 1.45 μ m (hkv1.3, in HEK 293 cells), 1.23 μ m (hkv1.5, in HEK 293 cells) |
biological field application | Calcium indicators; treating cancer,chronic bacterial infection,glaucoma,ocular hypertension,HIV-associated conditions,infectious diseases,neurodegenerative disorders,neurological conditions,psychiatric conditions |